{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:39:38Z","timestamp":1762004378227},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2012,1,3]],"date-time":"2012-01-03T00:00:00Z","timestamp":1325548800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0028115","type":"journal-article","created":{"date-parts":[[2012,1,4]],"date-time":"2012-01-04T00:44:37Z","timestamp":1325637877000},"page":"e28115","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Influence of IL28B Polymorphisms on Response to a Lower-Than-Standard Dose peg-IFN-\u03b1 2a for Genotype 3 Chronic Hepatitis C in HIV-Coinfected Patients"],"prefix":"10.1371","volume":"7","author":[{"given":"Luis F.","family":"L\u00f3pez-Cort\u00e9s","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Ruiz-Valderas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Jimenez-Jimenez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda F.","family":"Gonz\u00e1lez-Escribano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Almudena","family":"Torres-Cornejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosario","family":"Mata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Rivero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan A.","family":"Pineda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Marquez-Solero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pompeyo","family":"Viciana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of Grupo para el Estudio de las Hepatitis V\u00edricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2012,1,3]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jhep.2007.11.009","article-title":"Viral hepatitis and HIV coinfection.","volume":"48","author":"MS Sulkowski","year":"2008","journal-title":"J Hepatol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"Diagnosis, management, and treatment of hepatitis C: an update.","volume":"49","author":"MG Ghany","year":"2009","journal-title":"Hepatology"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa040842","article-title":"Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.","volume":"351","author":"FJ Torriani","year":"2004","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1001\/jama.292.23.2839","article-title":"Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.","volume":"292","author":"F Carrat","year":"2004","journal-title":"JAMA"},{"key":"ref5","first-page":"F27","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV\/HCV co-infected patients AIDS","volume":"18","author":"M Laguno","year":"2004"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1177\/135965350501000215","article-title":"Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.","volume":"10","author":"A Cargnel","year":"2005","journal-title":"Antivir Ther"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1365-2893.2006.00779.x","article-title":"Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients.","volume":"14","author":"M Crespo","year":"2007","journal-title":"J Viral Hepat"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1093\/jac\/dkp106","article-title":"Pegylated interferon-\u03b1 2a plus ribavirin versus pegylated interferon-\u03b1 2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.","volume":"63","author":"J Berenguer","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/hep.22598","article-title":"Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients.","volume":"49","author":"M Laguno","year":"2009","journal-title":"Hepatology"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1177\/135965350701200402","article-title":"Premature treatment discontinuation in HIV\/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin.","volume":"12","author":"V Soriano","year":"2007","journal-title":"Antivir Ther"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S0168-8278(09)60052-0","article-title":"Activity of telaprevir alone or in combination with peginterferon alfa-2a and ribavirin in treatment-na\u00efve genotype 2 and 3 hepatitis C patients. Interim results of study C209.","volume":"50","author":"GB Foster","year":"2009","journal-title":"J Hepatol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1067\/mcp.2000.110973","article-title":"Pegylated interferon-alpha 2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group.","volume":"68","author":"P Glue","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"ref13","article-title":"The pharmacokinetic behavior of pegylated (40 kD) interferon alfa-2a in chronic hepatitis C patients after multiple dosing.","volume":"32","author":"M Modi","year":"2000"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/clpt.2008.110","article-title":"Role of pegylated interferon-alpha-2a and ribavirin concentrations in sustained viral response in HCV\/HIV-coinfected patients.","volume":"84","author":"LF Lopez-Cortes","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1053\/jhep.2001.21747","article-title":"Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C.","volume":"33","author":"KR Reddy","year":"2001","journal-title":"Hepatology"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1111\/j.1572-0241.2004.30306.x","article-title":"Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial.","volume":"99","author":"PJ Pockros","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1053\/jhep.2001.26371","article-title":"A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.","volume":"34","author":"KL Lindsay","year":"2001","journal-title":"Hepatology"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/ng.449","article-title":"Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.","volume":"41","author":"Y Tanaka","year":"2009","journal-title":"Nat Genet"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/ng.447","article-title":"IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.","volume":"41","author":"V Suppiah","year":"2009","journal-title":"Nat Genet"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/0168-8278(91)90084-O","article-title":"Classification of chronic viral hepatitis: a need for reassessment.","volume":"13","author":"PJ Scheuer","year":"1991","journal-title":"J Hepatol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1310\/hct1101-1","article-title":"Degree of viral decline early in treatment predicts sustained virological response in HCV-HIV coinfected patients treated with peginterferon alfa-2a and ribavirin.","volume":"11","author":"M Rodriguez-Torres","year":"2010","journal-title":"HIV Clin Trials"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/j.1365-2893.2006.00768.x","article-title":"Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b.","volume":"13","author":"A Abergel","year":"2006","journal-title":"J Viral Hepat"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1365-2893.2005.00709.x","article-title":"Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg\/kg) combined with ribavirin in interferon-na\u00efve patients with chronic hepatitis C and up to moderate fibrosis.","volume":"13","author":"B Meyer-Wyss","year":"2006","journal-title":"J Viral Hepat"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.1365-2893.2008.00999.x","article-title":"Lower-than-standard dose peg-IFN alfa-2a for chronic hepatitis C caused by genotype 2 and 3 is sufficient when given in combination with weight-based ribavirin.","volume":"15","author":"O Weiland","year":"2008","journal-title":"J Viral Hepat"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/QAD.0b013e3282f1da99","article-title":"Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.","volume":"22","author":"L Martin-Carbonero","year":"2008","journal-title":"AIDS"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1002\/hep.22262","article-title":"A randomized, prospective trial of ribavirin 400 mg\/day versus 800 mg\/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3.","volume":"47","author":"P Ferenci","year":"2008","journal-title":"Hepatology"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/hep.23624","article-title":"Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes.","volume":"52","author":"MA Montes-Cano","year":"2010","journal-title":"Hepatology"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.jhep.2010.08.024","article-title":"Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin.","volume":"54","author":"TM Scherzer","year":"2011","journal-title":"J Hepatol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1086\/656235","article-title":"Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus.","volume":"51","author":"JA Pineda","year":"2010","journal-title":"Clin Infect Dis"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jhep.2010.07.041","article-title":"Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients.","volume":"54","author":"C Sarrazin","year":"2010","journal-title":"J Hepatol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0028115","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T20:16:27Z","timestamp":1686600987000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0028115"}},"subtitle":[],"editor":[{"given":"Matthew L.","family":"Albert","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2012,1,3]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2012,1,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0028115","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2012,1,3]]}}}